Chondrocyte proliferation promoter, chondrocyte proliferation promotion method, screening method for chondrocyte proliferation promoters

Patent metadata

Field	Value
Publication number	US-2020397827-A1
Application number	US-201916968436-A
Country	US
Kind code	A1
Filing date	Feb 13, 2019
Priority date	Feb 14, 2018
Publication date	Dec 24, 2020
Grant date	—

Abstract

A chondrocyte proliferation promoter containing, as an active ingredient, an agonist for at least adiponectin receptor 1 (PAQR1), adiponectin receptor 2 (PAQR2), adiponectin receptor 3 (PAQR3), and adiponectin receptor 4 (PAQR4); a chondrocyte proliferation promotion method using the chondrocyte proliferation promoter; and a screening method for chondrocyte proliferation promoters.

First claim

1 - 4 . (canceled)

5 . A chondrocyte proliferation promotion method, the method comprising:
contacting a chondrocyte with an agonist of adiponectin receptor 4 (PAQR4), wherein said method excludes a method for prevention or treatment of osteoarthritis.

6 - 9 . (canceled)

10 . A screening method for chondrocyte proliferation promoters, the method comprising:
determining whether a candidate material activates adiponectin receptor 4 (PAQR4); and selecting a candidate material that activates adiponectin receptor 4 (PAQR4).

11 . (canceled)

12 . The chondrocyte proliferation promotion method according to claim 5 , wherein the agonist is any of the following (a) to (c):
(a) a protein consisting of an amino acid sequence set forth in SEQ ID No: 3; (b) a protein consisting of a gC1q domain in the amino acid sequence set forth in SEQ ID No: 3; and (c) a protein having a sequence identity of 80% or more to the gC1q domain in the amino acid sequence set forth in SEQ ID No: 3 and acting as an agonist for adiponectin receptor 4 (PAQR4).

13 . A method for producing a chondrocyte proliferation promoter, excluding a chondrocyte proliferation promoter for treating or preventing osteoarthritis, the method comprising:
mixing an agonist for adiponectin receptor 4 (PAQR4) with at least one component selected from the group consisting of an excipient, a disintegrant, a binder, a lubricant, a surfactant, a buffer, a solubilizing aid, a stabilizer, a tonicity agent, a suspending agent, an emulsifier, a buffer, and a solvent.

14 . The method according to claim 13 , wherein the agonist is any of the following (a) to (c):
(a) a protein comprising an amino acid sequence set forth in SEQ ID No: 3; (b) a protein comprising a gC1q domain in an amino acid sequence set forth in SEQ ID No: 3; and (c) a protein having a sequence identity of 80% or more to the gC1q domain in the amino acid sequence set forth in SEQ ID No: 3 and acting as an agonist for adiponectin receptor 4 (PAQR4).

Assignees

• Univ Tokyo Science Found

Inventors

• Iwakura Yoichiro
• Murayama Masarfori

Classifications

• A61K38/19 Primary

  Cytokines; Lymphokines; Interferons · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61K31/4468

  having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl · CPC title

• C12N2501/999

  Small molecules not provided for elsewhere · CPC title

• A61K35/32 Primary

  Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane · CPC title